Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis
Objectives To systematically review and meta-analyse the evidence for effect modification by refractory status and number of treatment lines in relapsed/refractory multiple myeloma (RRMM); and to assess whether effect modification is likely to invalidate network meta-analyses (NMA) that assume negli...
        Saved in:
      
    
          | Main Authors: | Atle Fretheim, Christopher James Rose, Ingrid Kristine Ohm, Liv Giske, Gunn Eva Næss | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | BMJ Publishing Group
    
        2023-08-01 | 
| Series: | BMJ Open | 
| Online Access: | https://bmjopen.bmj.com/content/13/8/e067966.full | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma        
                          
 by: Adrian Schmidt
 Published: (2023-10-01)
- 
                
                    Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?        
                          
 by: Davor Galusic, et al.
 Published: (2025-01-01)
- 
                
                    Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma        
                          
 by: Claudio Cerchione, et al.
 Published: (2016-01-01)
- 
                
                    Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma        
                          
 by: Yi L, et al.
 Published: (2024-11-01)
- 
                
                    The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone        
                          
 by: Hitomi Nakayama, et al.
 Published: (2024-09-01)
 
       